Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khaja Mohsin

Internal Medicine Swansea, IL Medical Doctor

NPI 1730162108 CMS profile 124390

10 Emerald Ter, Swansea, IL 62226

Open in the dashboard

General payments

$4,574

238 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Khaja Mohsin of Swansea, IL is reported in the CMS Open Payments database as having received $4,574 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,367 62
2024 General $926 41
2023 General $648 33
2022 General $108 6
2021 General $767 50
2020 General $463 27
2019 General $295 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khaja Mohsin
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Khaja Mohsin were reported at $1,367. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Khaja Mohsin Internal Medicine median Middle half National median
2019 $295 $159 $48–$570 $163
2020 $463 $119 $33–$402 $114
2021 $767 $135 $37–$521 $132
2022 $108 $141 $42–$496 $149
2023 $648 $149 $45–$519 $160
2024 $926 $154 $47–$537 $164
2025 $1,367 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,644 126 payments
  2. Novo Nordisk Inc $280 14 payments
  3. Amarin Pharma Inc. $199 11 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $135 6 payments
  5. Lilly USA, LLC $131 6 payments
  6. AbbVie, Inc. $127 15 payments
  7. Global Blood Therapeutics, Inc. $108 5 payments
  8. GlaxoSmithKline, LLC. $100 6 payments
  9. Biohaven Pharmaceuticals, Inc. $94 6 payments
  10. Optos, Inc. $89 4 payments
  11. Other $668 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,574 238 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $1,158 52 payments
  2. BREZTRI $809 36 payments
  3. FARXIGA $516 30 payments
  4. Ozempic $267 13 payments
  5. RYBELSUS $267 13 payments
  6. Kerendia $135 6 payments
  7. NURTEC ODT $116 7 payments
  8. OXBRYTA $108 5 payments
  9. Vascepa $102 6 payments
  10. TRELEGY ELLIPTA $100 6 payments
  11. Other $1,876 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 144 drugs

Part D claims

9,093

Median for Internal Medicine: 777

Drug cost

$1,447,923

Median for Internal Medicine: $73,373

Branded share of claims

26%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 168 $224,794
Jardiance Empagliflozin Brand 160 $213,791
Farxiga Dapagliflozin Propanediol Brand 123 $156,614
Ozempic Semaglutide Brand 80 $127,294
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 62 $75,547
Linzess Linaclotide Brand 57 $69,030
Eliquis Apixaban Brand 54 $68,565
Rybelsus Semaglutide Brand 30 $51,825
Tresiba Flextouch U-100 Insulin Degludec Brand 39 $47,597
Entresto Sacubitril/Valsartan Brand 35 $45,831

The 10 drugs with the highest cost, of 144 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$51,411

Of which drugs: $61

Medicare patients

122

Average age 67

Services billed

895

66 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 55%
Arthritis 38%
Chronic kidney disease 29%
Ischemic heart disease 27%
Heart failure 25%
COPD 25%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 34 59 $47
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 42 121 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $454
$454 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $295
$295 62 —
MOUNJARO
  • Lilly USA, LLC $46
$46 28 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $42
$42 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $38
$38 123 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record